The stability test box for drugs produced and the comprehensive drug stability test box are used in multiple companies of Haiwang Biological Group

Haiwang Group was founded in Shenzhen in 1989. Over the past 29 years, Haiwang Group has focused on the pharmaceutical and health industry, insisted on taking innovation as the fundamental driving force for enterprise development, and has become a large backbone enterprise in China's pharmaceutical and health industry with a relatively complete industrial chain, strong independent innovation ability, and outstanding business model innovation ability. Its main business covers the whole industrial chain, such as medical and health product research and development, manufacturing, pharmaceutical logistics, chain pharmacies, the Internet, and general health. It has two listed companies under its umbrella. In 2017, the group's sales scale reached 50 billion yuan, with 30000 employees, and its comprehensive strength ranked among the top in China's pharmaceutical industry.

Leading brand value Firstly, the "Haiwang" brand created by Haiwang Group is the most influential brand in China's pharmaceutical and health industry, ranking high on the Chinese pharmaceutical industry brand value list for 15 consecutive years Firstly. In 2018, the brand value of "Haiwang" reached 68.579 billion yuan.

Outstanding innovation capability - Haiwang Group has domestically advanced independent innovation capabilities and a complete research and development system for pharmaceutical and health products. We have a national high-tech research and development plan industrialization base, a postdoctoral research workstation, and other national facilities Home Level R&D platform. It is one of the few pharmaceutical companies in China with the ability to develop first-class new drugs, and has achieved significant breakthroughs in the field of first-class new drug research and development.

Abundant achievements in business model innovation - Through business model innovation, Haiwang Group's pharmaceutical business and chain pharmacy business have developed rapidly. The sales scale of pharmaceutical commercial circulation in 2017 was about 28 billion yuan, and the network covers 21 provinces and cities across the country. Haiwang Xingchen Chain Pharmacy is Chinese The largest directly operated chain pharmacy in China, located in over 70 large and medium-sized cities, has more than 2600 stores and has consistently ranked among the top in terms of sales scale and tax revenue for many years Industry front. Column.

Industrial level strategic innovation - Currently, Haiwang Group is implementing a supply side reform model to fully promote industrial level innovation strategies in the procurement and supply of public hospital drugs and health products, rapidly building a billion dollar pharmaceutical and health innovation industry. In response to the current situation of inflated drug prices and ineffective administrative regulation in public hospitals, Haiwang Group actively responds to the national policy of reducing inflated drug prices, innovates the procurement and supply mode of public hospital drug groups with the concept of supply side reform, creates a new market-oriented drug supply mechanism, and significantly reduces the cost of drug procurement in public hospitals. This project is a major strategic innovation project aimed at changing the current situation of the pharmaceutical industry. In the field of health products, Haiwang Group's "Big Health Strategy" has entered the implementation stage. The sea king is shaking Overthrow the traditional pricing system, cut more than 80% of inflated pricing, cut all circulation costs, and create with a production capacity of billions Low Cost benefits the people. Produce health products that are affordable and trustworthy for every Chinese citizen.

The development goal - "Healthy China 2030 Plan Outline" has been officially promulgated, and the health industry has ushered in significant strategic development opportunities. Haiwang Group will take advantage of the situation, focus on the pharmaceutical and health industry, adhere to the equal emphasis on technological innovation and business model innovation, deepen innovation, practice hard, and strive to achieve the development goal of annual sales exceeding 200 billion yuan as soon as possible, and enter the Fortune Global 500.